Literature DB >> 18198387

Impact of glycosylation on antigenicity of simian immunodeficiency virus SIV239: induction of rapid V1/V2-specific non-neutralizing antibody and delayed neutralizing antibody following infection with an attenuated deglycosylated mutant.

Chie Sugimoto1,2,3, Emi E Nakayama4, Tatsuo Shioda4, Francois Villinger5, Aftab A Ansari5, Naoki Yamamoto3, Yasuo Suzuki6,1, Yoshiyuki Nagai7, Kazuyasu Mori1,2,3.   

Abstract

Infection of rhesus macaques with a deglycosylation mutant, Delta5G, derived from SIV239, a pathogenic clone of simian immunodeficiency virus (SIV), led to robust acute-phase viral replication followed by a chronic phase with undetectable viral load. This study examined whether humoral responses in Delta5G-infected animals played any role in the control of infection. Neutralizing antibodies (nAbs) were elicited more efficiently in Delta5G-infected animals than in SIV239-infected animals. However, functional nAb measured by 90% neutralization was prominent in only two of the five Delta5G-infected animals, and only at 8 weeks post-infection (p.i.), when viral loads were already below 10(4) copies ml(-1). These results suggest a minimal role for nAbs in the control of the primary infection. In contrast, whilst Ab responses to epitopes localized to the variable loops V1/V2 were detected in all Delta5G-infected animals at 3 weeks p.i., this response was associated with a concomitant reduction in Ab responses to epitopes in gp41 compared with those in SIV239-infected animals. These results suggest that the altered surface glycosylation and/or conformation of viral spikes induce a humoral response against SIV that is distinct from the response induced by SIV239. More interestingly, whereas V1/V2-specific Abs were induced in all animals, these Abs were associated with vigorous Delta5G-specific virion capture ability in only two Delta5G-infected animals that exhibited a functional nAb response. Thus, whereas the deglycosylation mutant infection elicited early virion capture and subsequent nAbs, the responses differed among animals, suggesting the existence of host factors that may influence the functional humoral responses against human immunodeficiency virus/SIV.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18198387     DOI: 10.1099/vir.0.83186-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  6 in total

1.  Simian Immunodeficiency Virus Targeting of CXCR3+ CD4+ T Cells in Secondary Lymphoid Organs Is Associated with Robust CXCL10 Expression in Monocyte/Macrophage Subsets.

Authors:  Masayuki Fujino; Hirotaka Sato; Tomotaka Okamura; Akihiko Uda; Satoshi Takeda; Nursarat Ahmed; Shigeyuki Shichino; Teiichiro Shiino; Yohei Saito; Satoru Watanabe; Chie Sugimoto; Marcelo J Kuroda; Manabu Ato; Yoshiyuki Nagai; Shuji Izumo; Kouji Matsushima; Masaaki Miyazawa; Aftab A Ansari; Francois Villinger; Kazuyasu Mori
Journal:  J Virol       Date:  2017-06-09       Impact factor: 5.103

2.  Improving immunogenicity of HIV-1 envelope gp120 by glycan removal and immune complex formation.

Authors:  Rajnish Kumar; Michael Tuen; Hualin Li; Doris B Tse; Catarina E Hioe
Journal:  Vaccine       Date:  2011-09-23       Impact factor: 3.641

3.  Glycosylation of simian immunodeficiency virus influences immune-tissue targeting during primary infection, leading to immunodeficiency or viral control.

Authors:  Chie Sugimoto; Shinichiro Nakamura; Shoko I Hagen; Yasuko Tsunetsugu-Yokota; Francois Villinger; Aftab A Ansari; Yasuo Suzuki; Naoki Yamamoto; Yoshiyuki Nagai; Louis J Picker; Kazuyasu Mori
Journal:  J Virol       Date:  2012-06-20       Impact factor: 5.103

4.  Human Immunodeficiency Virus and Simian Immunodeficiency Virus Maintain High Levels of Infectivity in the Complete Absence of Mucin-Type O-Glycosylation.

Authors:  James M Termini; Elizabeth S Church; Zachary A Silver; Stuart M Haslam; Anne Dell; Ronald C Desrosiers
Journal:  J Virol       Date:  2017-09-12       Impact factor: 5.103

5.  Protection of macaques with diverse MHC genotypes against a heterologous SIV by vaccination with a deglycosylated live-attenuated SIV.

Authors:  Chie Sugimoto; Satoru Watanabe; Taeko Naruse; Eiji Kajiwara; Teiichiro Shiino; Natsuko Umano; Kayoko Ueda; Hirotaka Sato; Shinji Ohgimoto; Vanessa Hirsch; Francois Villinger; Aftab A Ansari; Akinori Kimura; Masaaki Miyazawa; Yasuo Suzuki; Naoki Yamamoto; Yoshiyuki Nagai; Kazuyasu Mori
Journal:  PLoS One       Date:  2010-07-20       Impact factor: 3.240

6.  Phenotypic and Functional Characterization of Monoclonal Antibodies with Specificity for Rhesus Macaque CD200, CD200R and Mincle.

Authors:  Siddappa N Byrareddy; Dawn Little; Ann E Mayne; Francois Villinger; Aftab A Ansari
Journal:  PLoS One       Date:  2015-10-15       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.